On the stock market since 2000, it operates in the world of health and science. It has 19,000 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
The stock trades 36% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
A loss of $144.3M against $4.0B in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, CRL sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CRL has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.